Explore 3 Stock Ideas & Industry Insights Download Free Report

News

MiNK Therapeutics (NASDAQ:INKT) Edges Higher: What Investors Should Watch Next

● MiNK Therapeutics is one of the smaller, more speculative names in cell therapy, and its stock behaves accordingly, capable of sharp swings on modest volume.

Nitish Kishor | 10 September 2026

Humacyte, Inc (NASDAQ:HUMA) Drifts Lower: Is the Pullback Creating a New Setup?

● Notably, the roughly 3% decline came even as Humacyte announced positive news, underscoring that the move had no clear negative catalyst and likely reflects thin, low-priced trading rather than a fundamental shift.

Nitish Kishor | 10 September 2026

Volume Spike Alert: Healthy Extracts (OTC: HYEX) Slides as Trading Interest Surges

A sharp intraday slide has pushed Healthy Extracts Inc back onto the radar of speculative traders, even as the small nutraceutical company reports its fastest revenue growth in years. The move in HEALTHY EXTRACTS INC (OTCQB: HYEX) shares, flagged as a sharp drop on …

Nitish Kishor | 10 September 2026

Hyperfine (NASDAQ:HYPR) Stock Eases Back: Key Levels and Catalysts to Watch

● Hyperfine has spent 2026 trying to convince the market that portable, point-of-care brain imaging can become a durable commercial business, and the stock's slide back below a dollar shows how much work remains.

Nitish Kishor | 10 September 2026

IceCure Medical (NASDAQ:ICCM) Stock: Why Investors Are Reassessing the Cryoablation Developer

Momentum in the U.S. breast-cancer treatment market has become the defining theme for IceCure Medical Ltd (NASDAQ:ICCM), the Israeli developer of minimally invasive cryoablation technology.

Nitish Kishor | 10 September 2026

SeaStar Medical (NASDAQ:ICU) Stock: Revenue Climbs as QUELIMMUNE Adoption Grows

SeaStar Medical Holding Corporation (NASDAQ:ICU) gave investors a modest reason to cheer, with its shares climbing about 5% in a recent session. The Nasdaq-listed maker of a novel kidney-injury therapy, ticker ICU, has been building a commercial track record for QUELIMMUNE, its treatment for …

Nitish Kishor | 10 September 2026

IGC Pharma, Inc (NYSE American:IGC) Drifts Lower: Is the Pullback Creating a New Setup?

● The recent decline of roughly 3% is a small move with no single verified catalyst attached to the session, consistent with theVolatilitytypical of a sub-$1 stock.

Nitish Kishor | 10 September 2026

Gyre Therapeutics (NASDAQ:GYRE) Shares Slip: What's Pressuring GYRE and What Comes Next?

● Gyre Therapeutics is a biopharmaceutical company built around anti-fibrotic therapeutics, and it reached its current form after a corporate combination that gave a U.S.-listed shell exposure to an established Chinese pharmaceutical operation.

Nitish Kishor | 10 September 2026

Halberd Corp (OTC: HALB) Falls Sharply: Is This a Reset or a Deeper Warning Sign?

Penny stocks rarely tell a clean story, and Halberd Corporation (OTC: HALB) is a case study in why. The shares change hands at a fraction of a cent on the OTC market, so a single-session move of a few percentage points translates into a …

Nitish Kishor | 10 September 2026

Cue Health (OTC:HLTHQ) Went From NYSE Fanfare to Sub-Penny Silence

Cue Health Inc (OTC:HLTHQ) was once a celebrated pandemic-era diagnostics story, a San Diego company whose portable molecular test brought lab-grade COVID-19 detection into the home. Today the shares trade for about a millionth of a dollar on the over-the-counter market under a ticker …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…